A5057346186- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- Cancer therapeutics and mechanisms
- Metastasis and carcinoma case studies
- Cancer, Lipids, and Metabolism
- Pregnancy and preeclampsia studies
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Gastric Cancer Management and Outcomes
- Fibroblast Growth Factor Research
- Connexins and lens biology
- Skin Protection and Aging
- Retinal and Optic Conditions
- Brain Metastases and Treatment
- Electrochemical Analysis and Applications
- Vasculitis and related conditions
- Cardiovascular Health and Risk Factors
Sun Yat-sen University
2021-2025
Fujian Provincial Cancer Hospital
2017-2024
Fujian Medical University
2017-2024
Fudan University Shanghai Cancer Center
2024
Capital Medical University
2023
Sun Yat-sen University Cancer Center
2021
State Key Laboratory of Oncology in South China
2013
82th Hospital of Pla
2013
// Gen Lin 1 , Xirong Fan Weifeng Zhu 2 Cheng Huang Wu Zhuang Haipeng Xu Xiandong 3 Dan Hu Yunjian Kan Jiang Qian Miao and Chao Li 2, 4 Department of Thoracic Oncology, Fujian Cancer Hospital, Medical University Fuzhou 350014, China Pathology, Molecular Provincial Key Laboratory Translational Medicine, Correspondence to: Li, email: lichao3501@163.com Keywords: non-small cell lung cancer, prognosis, programmed death ligand 1, tumor infiltrating lymphocytes Received: June 20, 2017 Accepted:...
Background: Advanced non-small cell lung cancer (NSCLC) patients who harbor anaplastic lymphoma kinase (ALK) rearrangement are sensitive to an ALK inhibitor (crizotinib), but not all ALK-positive benefit equally from crizotinib treatment. We analyze the impact of TP53 mutations on response in with NSCLC. Methods: Sixty-six NSCLC receiving were analyzed. 21 cases detected successfully by next generation sequencing validation FFPE before crizotinib. evaluated 8 relation disease control rate...
Abstract Age is closely related to human health and disease risks. However, chronologically defined age often disagrees with biological age, primarily due genetic environmental variables. Identifying effective indicators for in clinical practice self-monitoring important but currently lacking. The lens accumulates age-related changes that are amenable rapid objective assessment. Here, using photographs from 20 96-year-olds, we develop LensAge reflect aging via deep learning. correlated...
Preeclampsia (PE), a severe hypertensive disorder during pregnancy, significantly contributes to maternal and neonatal mortality. Existing prediction biomarkers are often invasive expensive, hindering their widespread application. This study introduces PROMPT (Preeclampsia Risk factor + Ophthalmic data Mean arterial pressure Prediction Test), an AI-driven model leveraging retinal photography for PE prediction, registered at ChiCTR (ChiCTR2100049850) in August 2021. Analyzing 1812 pregnancies...
Abstract Background The development of non‐small cell lung cancer (NSCLC) is associated with the deregulation circRNAs. objective this study was to investigate effects circ‐RAD23B in NSCLC. Methods Circ‐RAD23B expression, miR‐142‐3p and MAP4K3 detected by qPCR. Cell proliferation investigated CCK‐8 assay colony formation assay. migration invasion were assessed transwell Angiogenesis ability tube cycle distribution apoptosis monitored flow cytometry. predicted binding relationship between or...
Purpose: Tumor mutational burden (TMB) calculated by whole-exome sequencing (WES) is proved to be effective predict the clinical benefit of immune checkpoint blockades. However, WES not commonly used in China. We aimed determine if a 381-caner-gene panel (CGP) could estimate TMB, delineate landscape TMB Chinese patients and identify mutated genes pathways related higher TMB. Methods: first evaluated correlation between estimated 381-cancer-gene MasterView using data from melanoma sample...
Abstract Background The association between lipid metabolism disorder and carcinogenesis is well-established, but there limited research on the connection metabolism-related genes (LRGs) lung adenocarcinoma (LUAD). objective of our was to identify LRGs as potential biomarkers for prognosis assess their impact immune cell infiltration in LUAD. Methods We identified novel prognostic LUAD patients via bioinformatics analysis. CYP27A1 expression level systematically evaluated various databases,...
There are few reports of IgA nephropathy (IgAN) with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.The authors report the clinical and pathological findings in 14 patients IgAN ANCA seropositivity.These retrospective cases consisted 4 men 10 women a mean age 44.4 ± 12.7 years. ANCA-positivity was documented by EUROBlot kits indirect immunofluorescence all patients. The results were positive (12 MPO-ANCA, 2 PR3-ANCA). Indirect P-ANCA, C-ANCA). Three ANCA-positive...
Abstract Nuclear factor‐kappa B ( NF ‐κB) as a prognostic marker remains unclear in non‐small cell lung cancer NSCLC ). Here, we studied ‐κB‐p65 (p65) expression and phosphorylated ‐κB‐p105 (p‐p105) correlated the finding with overall survival OS ) clinicopathological features. A total of 186 archival samples from patients surgically resectable were probed p65 p‐p105 (Ser 932). The p65‐positive p‐p105‐positive defined distinct nuclear cytoplasmic labelling at least 1% tumour cells,...
ALK rearrangement-advanced NSCLC patients respond to crizotinib. rearrangement is currently determined with RT-PCR. VENTANA IHC a standard method identify protein overexpression in NSCLC; however, has rarely been used determine the response crizotinib Chinese and overexpression. To better clarify clinical implication of detect rearrangements, we conducted this study analyze RT-PCR large cohort undergoing screening for rearrangements. A total 1720 who had rearrangements detected by and/or...
To examine the expression of D-dimer, fibrinogen (FIB), leukocyte, C-reactive protein (CRP) and tissue factor (TF) released from monocyte in non-small cell lung cancer (NSCLC) patients with or without venous thromboembolism (VTE) analyse correlation, to explore possible mechanisms.Seventy-two confirmed diagnosis cancer, among whom 10 VTE were enrolled into study November 2012 January 2014 First Affiliated Hospital Fujian Medical University 30 healthy subjects also as control group. Ficoll...
e13539 Background: Screening of c-mesenchymal-epithelialtransition (MET) gene fusions in non-small cell lung cancer (NSCLC) patients enables the identification likely to benefit from type I or II MET inhibitors. The aim this study was evaluate prevalence Chinese NSCLC populations, which had not been reported earlier, and describe targeting potential populations. Methods: A multicenter China initiated February 2014, have enrolled as December 2017. Capture-based comprehensive genomic profiling...
Background: Mortal obligate RNA transcript (MORT), a long noncoding RNA, has been reported as potential tumor suppressor in many types of cancer. The functions MORT involved lung adenocarcinoma (LUAD) were investigated this study. Materials and Methods: A total 67 patients with LUAD (adenocarcinoma) recruited Quantitative reverse transcription-polymerase chain reaction was used to assess gene expression. Cell transfections analyze interactions. Transwell migration invasion assay carried out...
e23138 Background: Activation of c-MET lead to a wide range biological activities. MET has recently been identified as novel promising target in NSCLC, some inhibitors have developed. The primary aim this study was evaluate the amplification status advanced NSCLC and compare consistency analyses metastatic lymph nodes tumor tissue.Methods: Real-time fluorescent quantitative polymerase chain reaction used test tissues 368 patients NSCLCs 178 paired samples compared amplifications inmetastatic...
Vinpocetine exerts pharmacological effects against cardiovascular diseases, while few studies focused on its roles in cancer. The present study investigated the of vinpocetine non-small cell lung cancer (NSCLC) and relationship with cisplatin resistance. A549 cisplatin-resistant cells (A549/DDP) nuclear factor erythroid 2-related 2 (Nrf2)-overexpressing lines were established. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay was conducted to...
e14050 Background: EGFR gene mutations were discovered in some of NSCLC patients. Two major include 19del and L858R. These account for more than 90% all related to TKIs sensitivity. Icotinib, an TKI, showed equivalent response rates better tolerability compared with gefitinib, double blind trial (ICOGEN) advanced previously treated China. In addition, other uncommon have been identified. The efficacy icotinib patients harboring these is still unknown. This study investigated the carrying...
e13538 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and rare or atypical EGFR mutations had been identified. Such exons 18-25 kinase domain duplications (KDD) fusions (EGFR-RAD51 EGFR-PURB), importance of signaling pathogenesis lung cancer efficacy EGFR-TKI treatment demonstrated. The aim this study was to evaluate prevalence Chinese NSCLC patients, association between these molecular alterations clinicopathological...
e14515 Background: Pembrolizumab proves to be effective for clinical treatment of non-small cell lung cancer (NSCLC). The application pembrolizumab should hinged on the magnitude PDL1 expression justified by 22C3 assay Dako platform. However, whether another diagnostic assay, SP142, can replace in pembrolizumab-based immunotherapy thus far remains largely unknown. Methods: Forty-nine cases were randomly collected from 207 NSCLC patients with known PD-L1 detected 22C3. Each case was stained...
e13002 Background: ERBB2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers (NSCLC) and ERBB2-directed therapies have shown promising results this unique population, while little is known about fusion association with outcomes of afatinib. The aim study was investigate the efficacy afatinib patients advanced NSCLC. Methods: A multicenter China initiated from February 2014, NSCLC enrolled as December 2018. To determine frequency fusions other tumors, we...
e13001 Background: Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in non-small cell lung cancer (NSCLC) biology given the frequency of molecular alterations and vast interface multiple other signaling pathways. Furthermore, numerous FGFR inhibitors clinical development demonstrate expanding therapeutic relevance this pathway. The aim study was to evaluate prevalence FGFR-TACC fusions Chinese NSCLC populations, which had not been reported...